| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9388cb841605d5dcfeb6bc6d60f4384a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a135a933620c99beab01d4ac785d25 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-712 |
| filingDate |
2015-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97d2ab2d699b7bb52bf714d3f98ba50a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc857c67f79504c89645ace6de81c495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61f6df8b6fc2c9cced4b5680378c7908
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d167470a254ac5f8659cc1d9e90ef72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2406b0e3a7dbcec7ce0e1d330998bbf1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb04049846936ec0ebaec4b73f6007c5 |
| publicationDate |
2017-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2897389-A1 |
| titleOfInvention |
Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer |
| abstract |
Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113648431-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018129622-A1 |
| priorityDate |
2015-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |